Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gandakang Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Aodong Yanbian Pharmaceutical for the treatment of chronic hepatitis B. It is specifically indicated for patients presenting with the TCM syndrome of liver stagnation, spleen deficiency, and blood stasis. The formulation is composed of several herbal extracts, including *Astragalus membranaceus* and *Salvia miltiorrhiza*, which are traditionally used to protect liver cells, improve microcirculation, and modulate the immune response. Clinical development has included Phase 2 trials (e.g., CTR20131656) to evaluate its safety and efficacy compared to earlier formulations in adult populations with chronic viral hepatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gandakang Capsule.